Sage Journals: Discover world-class research

Abstract

Background: Physical activity has been shown to improve motor symptoms in numerous Parkinson’s Disease (PD) clinical trials. However, the relationship between physical activity (PA), patient-reported outcomes, and quality of life (QoL) in a community-dwelling cohort has not been well-characterized. Methods: To evaluate this association, data were obtained from the internet-based Modifiable Variables in Parkinsonism Study (n = 415). Patient-reported outcomes and QoL were assessed by the Patient-Reported Outcomes in Parkinson’s Disease (PRO-PD) and Patient-Reported Outcomes Measurement Information System (PROMIS), respectively. Regression models controlled for age, sex, and disease duration. Results: As PA increased, PROMIS scores increased (P < 0.001) and motor and non-motor symptom PRO-PD scores decreased (P < 0.001) implying improved symptoms and QoL. The association between PA and symptom severity was significant in women, but not men. Conclusions: These data may imply improved symptoms and QoL with increased PA frequency in individuals with PD. Sex differences in the relationship between PA and PD outcomes warrant further investigation.

Keywords

pragmatic patient-centered observational natural history clinical epidemiology

Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative disorder manifest by motor symptoms including tremor, rigidity, bradykinesia, and postural instability,¹ as well as a variety of non-motor issues including sleep, mood, motivation, and cognition.² Both motor and non-motor symptoms can impact quality of life (QoL).² The global prevalence of PD is rising rapidly, and in 2021, it was estimated that there were over 11.7 million individuals with PD, representing a substantial morbidity and mortality burden.³ While there is no cure for PD, medications (eg, dopaminergic replacement therapy [DRT]), surgical interventions, and other therapies can help to relieve some symptoms.^4,5 While DRT can improve PD motor symptoms, it can also worsen many non-motor symptoms (NMS).⁶ Consequently, there is substantial interest in non-pharmacological options for treating PD.⁷

Physical activity (PA) is defined as any movement of the body that uses energy, whereas exercise is a specific type of PA that is planned, structured (characterized by frequency, intensity and time) and performed with the purpose of improving physical fitness.⁸ Thus, all exercise is PA while not all forms of PA qualify as exercise. Evidence in the literature has demonstrated that exercise and other forms of PA can ease PD motor symptoms, improve functioning, and perhaps slow the clinical progression of PD.^9-12 Maintenance of motor functions (eg, gait, balance, and muscle strength) is critical because it enables the safe performance of daily activities, which in turn, helps individuals to maintain independence.¹⁰ Randomized controlled trials have shown that moderate- to vigorous-intensity PA performed for at least 30 minutes, three times per week, improves the severity of motor symptoms and can slow the progression of symptoms over three to six months,^13-15 and a recent proof-of-concept study provided evidence that sustained periods of higher intensity PA have neuromodulatory effects in PD.¹⁶ PA interventions may also have a positive impact on NMS (eg, improvements in depression and anxiety¹⁷), but the evidence is limited compared to the effect on motor symptoms.^11,18,19 People living with PD have identified a need for advice about accessible and low-cost lifestyle changes, including exercise, to enhance their wellness, sense of agency, daily functioning, and QoL.²⁰

In 2021, the Parkinson’s Foundation and the American College of Sports Medicine issued updated PA recommendations for individuals with PD. The guidelines recommend 150 minutes of moderate- to vigorous-intensity exercise (ie, 40%-60% heart rate reserve [HRR] and 60%-85% HRR, respectively) each week, albeit only after evaluation by a physical therapist specializing in PD. The updated guidelines specifically recommend that individuals complete aerobic activities three days per week for at least 30 minutes per session of continuous or intermittent movement at moderate- or vigorous-intensity, and complete strength training activities on two or three non-consecutive days per week for at least 30 minutes per session for 10-15 repetitions for major muscle groups.²¹ The guidelines also recommend integrating balance and stretching activities at least two to three days per week.²¹

PA interventions in PD populations are often trialed under highly controlled, optimal research conditions. Individuals are typically asked to complete structured PA interventions and are continuously monitored (ie, directly supervised in a laboratory or other setting (eg, the SPARX3 Study²²), or remotely observed with digital activity trackers, such as pedometers, accelerometers and heart rate monitors (eg, the STEPWISE study²³)) throughout the trial period, although some behavior change programs have also been trialed (eg, the ParkFit Program²⁴). However, adaptations of PA interventions are common when they are delivered at-scale and may impact intervention effectiveness.²⁵ There is limited evidence available on the relationship between PA levels and PD outcomes in an unsupervised real-world context. Therefore, additional research is needed to elucidate the potential associations between the frequency and intensity of PA and PD outcomes.

The aim of this study was to assess the relationship between PA frequency and PD outcomes, including motor symptoms, NMS, and QoL in people with PD in a naturalistic environment.

Methods

Data Collection

Data were obtained from the Modifiable Variables in Parkinsonism (MVP) Study. The MVP, initiated in 2013, is a prospective, observational natural history study designed to elucidate lifestyle variables associated with rate of PD progression. The MVP Study was approved using the Bastyr University Institutional Review Board (IRB; #13A-1332) and listed on ClinicalTrials.gov (#NCT02194816). Study participants were recruited via Washington State Parkinson Disease Registry, Michael J Fox Foundation Trial Finder, through social media advertising and in-person through community lectures and outreach around the country. Due to this being an online survey, the IRB issued a Waiver of Documentation of Informed Consent. All study participants included in this analysis reviewed the Participant Information Sheet and provided consent via the online survey. All individuals confirmed that they read and understood the participant information sheet prior to study participation. Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Bastyr.^26,27 REDCap is a secure, web-based software platform designed to support data capture for research studies, providing: (i) an intuitive interface for validated data capture; (ii) audit trails for tracking data manipulation and export procedures; (iii) automated export procedures for seamless data downloads to common statistical packages; and (iv) procedures for data integration and interoperability with external sources.

At the baseline visit, all individuals with PD are asked for information about their diagnosis. While individuals with any form of parkinsonism, or evidence of prodromal parkinsonism, are eligible to participate in the MVP study, only individuals reporting a diagnosis of “Parkinson’s disease/ Idiopathic Parkinson’s disease (PD)” were included in this analysis. The data presented here are a cross-sectional analysis of baseline data of those individuals.

Outcome Measures

The MVP Study is an internet-based study designed to identify variables associated with the rate of patient-reported PD severity and progression. As this analysis utilized an existing database, the data dictionary was reviewed for all assessments related to PA, QoL, and PD severity. The variable “PD eHY stage” was an attempt to estimate Hoehn and Yahr remotely; participants were asked, “Which stage best represents your disease?” and given a drop-down menu with the following choices: “1-sided symptoms only, minimal disability,” “Both sides affected, balance is stable,” “Mild to moderate disability, balance affected,” “Severe disability, able to walk and stand without help,” “Confined to a bed or wheelchair, unless aided,” or “Don’t know.” (Table 1).²⁸ We identified two primary outcome measures of interest that were available through the MVP study database: the Patient-Reported Outcomes in Parkinson’s Disease (PRO-PD) scale and the Patient-Reported Outcomes Measurement Information System (PROMIS) Global scale.

Table 1.

Demographic and Disease Characteristics of the Cohort.

Characteristics	Total Cohort (n = 415)	Males (n = 176)	Females (n = 239)	P-Value
Characteristics	Mean (SD)	Mean (SD)	Mean (SD)	P-Value
Age (years)	65.4 (8.3)	66.1 (8.7)	64.9 (8.0)	0.13
PD duration (years)	6.8 (5.0)	6.4 (4.9)	7.1 (5.1)	0.17
PD eHY stage	1.8 (1.0)	1.8 (1.0)	1.7 (1.0)	0.53
PRO-PD total	777.4 (485.8)	794.3 (473.6)	765.7 (500.6)	0.56
Motor	303.7 (217.1)	309.9 (211.1)	300.3 (223.9)	0.66
Non-motor	473.6 (288.0)	484.5 (279.9)	465.3 (297.2)	0.51
PROMIS	37.3 (6.7)	37.4 (6.2)	37.2 (7.1)	0.80
PA (days/week)	4.5 (1.9)	4.6 (1.8)	4.5 (2.0)	0.61

P-values are derived from independent samples t tests comparing mean values between male and female participants. PD, Parkinson’s Disease; PRO-PD, patient-reported outcomes in Parkinson’s Disease; PROMIS, Patient-Reported Outcomes Measurement Information System; PA, physical activity.

The PRO-PD scale is a validated measure for PD symptom severity.²⁹ Patient-reported outcomes (PRO) are increasingly recognized as appropriate complements to traditional clinical trial measures, and they allow patient perceptions to be considered in the definition of treatment success.^30,31 The total PRO-PD score provides the cumulative scale of 32 slider bars that each evaluate a different PD symptom.³² PRO-PD has been shown to correlate with well-validated endpoints in PD including Unified Parkinson’s Disease Rating Scale, Hoehn/Yahr stage, years since diagnosis, quality of life, and the Non-Motor Symptom Scale in cross-sectional analysis.³²

For this analysis, the total PRO-PD, as well as motor and non-motor subsets, were included as outcomes. The PRO-PD motor subset consisted of the following symptoms: walking, rising from a seated position, tremor, freezing of gait, dressing/eating/grooming, balance, frequent falls, dyskinesia, handwriting, bradykinesia, speech, and stooped posture. The PRO-PD non-motor subset included the variables: constipation, lack of motivation, depression, loss of interest, anxiety, fatigue, daytime sleepiness, temperature dysregulation, orthostatic hypotension, visual disturbances, insomnia, rapid eye movement (REM) sleep behavior disorder, muscle pain, drooling, memory impairment, comprehension disability, hyposmia, sexual dysfunction, urinary dysfunction, and hallucinations.

The 10-question PROMIS Global Scale was chosen as the primary QoL measure for this analysis. The PROMIS Global Scale measure has been validated across diverse chronic conditions and meets the “Recommended” criteria for utilization by the International Parkinson and Movement Disorder Society Task Force on Rating Scale.³³ For PA frequency, participants were asked “On how many of the last seven days did you participate in at least 30 min of physical activity?”

Statistical Analyses

Descriptive statistics were used to characterize demographic and disease characteristics of the cohort and independent samples t-tests were used to assess for group differences between male and female participants. Multiple linear regression models were developed to examine the association between self-reported PA (measured as days/week that the participants completed at least 30 minutes of PA) and patient-reported outcomes (PRO) with total PRO-PD score, PRO-PD motor items, PRO-PD non-motor items or PROMIS scores used as the dependent variable. The linear regression analyses controlled for age, years since diagnosis, and sex. Participant records were excluded from the linear regression analyses if age, years since diagnosis, and/or sex data were missing. Associations of individual symptom scores with PA were assessed using partial correlations, controlling for age, sex, and disease duration. Because enrollment in the MVP Study has historically included a large proportion of female participants, we also examined separate models to assess associations separately in males and females. Only participants reporting a diagnosis of idiopathic PD were included in this analysis. For participants who did not score an element from the 33 individual PRO-PD symptoms, the cohort average for that individual symptom was substituted for any missing values. For other data analyses, such as QoL measures, the most complete dataset was utilized for the relevant variables. Statistical analyses were conducted in SPSS (IBM, Armonk, NY) with alpha level set to 0.05. In this exploratory study, no adjustments were made for multiple comparisons to avoid increasing the risk of type II errors and prevent excluding potential associations that may be explored in future studies.

Results

This study included 415 participants with a self-reported diagnosis of PD; 58% of participants were women. Mean (SD) age and PD disease duration were 65.4 (8.3) and 6.8 (5.0) years, respectively. Participants reported exercising for at least 30 minutes an average of 4.5 (1.9) days per week. Characteristics of the cohort, including a comparison of male and female participants, are detailed in Table 1.

More Frequent PA is Associated with Improved PRO and QoL in PD

PRO-PD total motor and non-motor scores each decreased (indicating less severe symptoms) with increasing PA frequency (Figure 1A). Similarly, PROMIS scores increased (indicating greater QoL) with more frequent PA (Figure 1B). For each outcome, there was a significant dose-response between activity levels and patient-reported scores (ANOVA P < 0.001, Figure 1).

Figure 1.

Higher levels of physical activity are associated with better patient reported outcomes. (A) Histogram illustrating self-reported days per week of physical activity. (B-D) Boxplots representing median (horizontal lines within box) and interquartile range (box) of scores for PRO-PD total (B); PRO-PD motor items (C) PRO-PD nonmotor items (D); PROMIS (E) as a function pf activity frequency. Whiskers represent variability up 1.5 times the interquartile range. Outliers are represented by individual dots. P-value for trend <0.001 for association between the amount of self-reported activity and each PRO scale/subscale (A) or PROMIS. Higher PRO-PO score indicate worse symptom burden, whereas, higher PROMIS scores indicate improved quality of life. PRO-PO, Patient reported outcomes in Parkinson’s disease. PROMIS, Patient-Reported Outcomes Measurement Information System.

Association of Individual Motor and Non-motor PD Symptoms with PA Frequency

Most, but not all, motor and non-motor domains were inversely associated with the frequency of PA (Figure 2). Using partial correlations controlling for age, sex, and disease duration, PA showed the strongest inverse association with walking, arising from a chair, balance, and dressing among motor symptoms (Table 2). Among NMS, problems with motivation, excessive sleepiness, and sexual dysfunction demonstrated the strongest inverse association with PA frequency. Conversely, cognitive complaints including memory and comprehension scores as well as smell loss were not significantly associated with PA.

Figure 2.

Association between individual Parkinson’s disease symptom domains and physical activity levels. Data are average raw scores for each symptom as a function of days per week of physical activity. Higher scores are towards the outside of the circle and imply worse symptom burden. Smell, sense of smell; Const, constipation; Dizzy, dizziness upon standing; Urinary, urinary dysfunction; Sexual, sexual dysfunction; Sleepy, daytime sleepiness; Depress, depression; Motiv, motivation; Interest, withdrawn/loss of interest; Comp, comprehension; Halluc, hallucinations; Visual, visual disturbances; Pain, muscle pain; RL, restless legs; RBD, REM Sleep Behavior Disorder; Drool, drooling; Balance, balance impairment; Freeze, freezing of gait; Stoop, stooped posture; Dress, dressing, grooming, eating; Rising, difficulty rising from seated position; Gait, gait impairment; Dysk, dyskinesia; Writing, handwriting; Brady, bradykinesia.

Table 2.

Correlation Between Individual Motor and Non-motor Parkinson’s Disease Symptoms and Physical Activity Levels.

Parkinson’s Disease Symptoms	Correlation Coefficient (r)	P-Value
Motor symptoms
Walking	−0.256	<0.001
Rising from seated	−0.220	<0.001
Dressing	−0.216	<0.001
Balance	−0.208	<0.001
Tremor	−0.183	<0.001
Freezing	−0.170	<0.001
Falls	−0.163	0.002
Dyskinesia	−0.163	0.002
Handwriting	−0.151	0.003
Slowness	−0.137	0.008
Speech	−0.104	0.04
Stooped posture	−0.081	0.12
Non-motor symptoms
Motivation	−0.174	<0.001
Sexual dysfunction	−0.173	<0.001
Sleepy	−0.167	<0.001
Restless legs	−0.149	0.004
Withdrawn	−0.146	0.005
Pain	−0.140	0.007
Urinary	−0.139	0.007
Fatigue	−0.131	0.011
Drooling	−0.131	0.011
Constipation	−0.129	0.013
Visual	−0.128	0.013
Insomnia	−0.127	0.014
Acting out dreams	−0.122	0.018
Depression	−0.117	0.023
Anxiety	−0.114	0.027
Dizzy	−0.100	0.053
Nausea	−0.088	0.090
Memory/forgetfulness	−0.079	0.126
Comprehension	−0.056	0.279
Sense of smell	0.018	0.721

Data are partial correlations (controlling for age, sex, and disease duration) between individual symptoms and days/week of reported physical activity and associated P-values (significant P-values are in bold).

Sex-specific Association Between PA, PRO, and QoL in PD

Consistent with the unadjusted analysis presented in Figure 1, activity levels were inversely associated with symptom severity and positively associated with quality of life in multivariate linear regression models, when controlling for age, sex, and disease duration (Table 3). Men and women reported similar levels of activity PRO-PD total and motor scores (and for most individual symptom domains). However, in separate multivariate linear regression models including only male or female participants, the association between PA frequency and symptom severity was significant only in women (Table 3).

Table 3.

Sex-specific Differences in the Associations Between Physical Activity and Patient Reported Outcomes in Parkinson’s Disease.

Outcome Measures	Total Cohort		Males		Females
Outcome Measures	β	P-Value	β	P-Value	β	P-Value
PRO-PD total	−57.2	<0.001	−27.0	0.15	−69.2	<0.001
Motor	−25.0	<0.001	−14.4	0.08	−32.0	<0.001
Non-motor	−23.8	<0.001	−12.3	0.26	−39.2	<0.001
PROMIS	0.85	<0.001	0.29	0.29	1.26	<0.001

Data shown are beta coefficients (for physical activity level) and P-values derived from multiple linear regression models with the PRO indicated as the dependent variable and physical activity, age, sex, and PD duration as independent variables. Analogous models were run using data from the entire cohort, males only, and females only, as indicated. PRO-PD, Patient-Reported Outcomes in Parkinson’s Disease; PROMIS, Patient-Reported Outcomes Measurement Information System.

Discussion

Overall, participants with higher levels of PA had less severe total, motor, and non-motor PD symptoms, as well as higher QoL. Although a variety of PA interventions have been shown to improve PD motor outcomes in the highly controlled settings of clinical trials, less is known about the relationship between activity levels in community settings and important patient-centered outcomes.^34,35 People living with PD have identified a need for additional information about accessible, low cost lifestyle interventions to improve their QoL.²⁰ Providing individuals with guidance for PA from the day of diagnosis has been identified as a strategy to improve self-agency and instill hope for individuals with PD.³⁶ The results of this study suggest that PA interventions for individuals with PD can successfully be translated to community settings, given that improvements in PD outcomes were observed in an unsupervised real-world context. However, this cohort reported higher levels of PA (4.5 days/week on average) than prior reports in both early and mixed stage PD populations.^37-40 Given their willingness to participate in the MVP study, it is possible that this cohort is also more motivated to participate in PA than the general PD population.

The findings from this study also suggest that improvements in patient-reported outcomes from PA are dose-dependent (Table 3). Specifically, the results indicate completing PA five to seven days per week provides maximum benefits. This has implications for clinical recommendations and suggests that health care providers should (i) emphasize that the recommendations represent the minimum amount of PA that individuals with PD should complete, and (ii) recommend that individuals with PD try to incorporate additional PA above the minimum each week to maximize benefits, provided that their individual health status allows for the safe completion of activities.

The use of PRO in this study provided valuable information about the association between PA levels and specific PD symptoms. PRO are underutilized in clinical trials and provide important information not often captured by traditional assessments.^41-43 Motor symptoms were broadly associated with activity levels (Figure 2, Table 2), reminiscent of improved overall motor function in numerous trials of aerobic, resistance, and balance PA interventions in PD.^44-47 However, there is limited evidence in the literature examining the potential link between PA and NMS.^11,18,19 This study demonstrated strong inverse associations between problems with motivation, excessive sleepiness, sexual dysfunction, and PA frequency (Table 2). The observed relationship between sleep-related symptoms and PA activity was consistent with results from a recent interventional PA trial where sleep was the primary outcome.⁴⁸ However, cognitive symptoms (memory, comprehension) were not significantly associated with PA in this study (Table 2), in contrast to clinical trial data suggesting that PA improves cognition in PD.^49,50 While this inconsistency may relate to the use of subjective rather than objective cognitive measures or intensity of PA, it highlights the need to target non-motor outcomes in PA trials using validated scales.

Higher self-reported QoL, measured by the PROMIS Global Scale, was strongly associated with increased PA frequency (Figure 1, Table 3). Previous interventional trials of PA in PD have generally failed to demonstrate this relationship,^51,52 in part, because QoL has been inconsistently included as an outcome. However, a systematic review and meta-analysis indicated that PA interventions, especially aerobic exercise, can significantly improve QoL in individuals with PD, although certain domains of QoL (ie, mobility, activities of daily life, and social support) improved more than others and there was high heterogeneity among included studies.⁵³

In sex-specific multivariate models, the association between PA and PRO was only statically significant in women. Studies in the general population have reported that women are somewhat less active than men, implying that there could be a differential benefit to increasing PA levels.⁵⁴ Furthermore, women may preferentially engage in different types or intensity of PA and derive cardiovascular benefits of PA at lower intensity than men.^55,56 However, the sex differences observed in this study must be reproduced in independent cohorts, and the potential mechanisms and implications warrant further investigation. Bespoke guidelines for wellness strategies that account for age, gender, and other sociodemographic factors are needed, as large gaps have been identified in the management of these populations in the PD context.⁵⁷

This study has limitations that should be acknowledged and considered in the interpretation of the findings. Relying on participant self-report of a diagnosis, instead of a neurological evaluation performed by a trained clinician, is a limitation of this study. Individuals with PD can misunderstand the diagnosis, cognitive impairment can interfere with ability to understand or recall the diagnosis, and individuals with PD may be misdiagnosed early in the disease, either due to lack of specialist involvement or the overlapping presentations of different forms of parkinsonism early in the disease. This diagnostic certainty is further complicated as the defining characteristics of PD are still evolving.⁵⁸ Data regarding daily dopamine use for participants was not available.

Another limitation of the study is that “physical activity”, which includes daily tasks like walking, household chores, gardening, sports, and workout routines, and “exercise,” which is specifically intended to enhance physical health, are not defined in the study. This can create conceptual confusion, diluting the clarity of the findings, and introduces validity concerns, as participants may only be reporting exercise and thus underestimating overall PA. Despite these limitations, this simplified messaging can aid in pragmatic public messaging in supporting a “Just Do Something” approach. Subsequent analyses should include a validated measure for PA, which was not available for this analysis.

Due to the cross-sectional nature of the data used in this study, it is not clear whether a lower level of symptom severity allows for a higher level of PA or if a higher level of PA leads to improved symptom severity and function in individuals with PD. It is also possible that both effects occur and contribute to a positive feedback loop. For example, walking symptoms were better in participants with higher PA levels, and it seems equiprobable that participants with better gait (or other motor symptoms) might be more active, or that PA could improve gait symptoms (Table 2). Additionally, PRO are subjective by nature and PA levels were self-reported in this study. Therefore, these data were subject to potential recall bias. However, self-reported PA levels have been shown to have a high level of agreement with objectively measured step counts in at least one PD cohort.³⁸ Additionally, each symptom in PRO-PD is assessed through a single question allowing for stratification by symptoms. Future studies using detailed, validated questionnaires targeted at domains of interest may yield additional information.

This study assessed PA frequency, but information about the intensity or type of PA was not available. Evidence indicates that PA intensity may be an important factor that contributes to the efficacy in improving PD outcomes,^13,14,59 although an observational study suggested that a larger volume of PA, regardless of the intensity, is associated with slower disease progression.⁶⁰ A systematic review and meta-analysis also demonstrated that most different types of exercise have a beneficial effect on both the severity of PD motor symptoms and QoL.⁹ The questionnaires used in concert with the PRO-PD scale have been modified to collect information on PA type and intensity for future studies.

Conclusion

This study demonstrated that higher PA levels are associated with better patient-reported motor symptoms, NMS, and QoL in PD. Future research should focus on the potential sex differences in the association between activity levels and PD outcomes, as this could offer insights into the relationship between PA and PD symptoms. The remotely acquired PROs, PROMIS and PRO-PD, were sensitive to changes in PA frequency and provided a unique description of patient-perceived symptoms associated with lack of PA in a real-world setting. Based on self-reported PA frequency data, 6-7 days per week of PA may be associated with improved PROs in PD.

Footnotes

Acknowledgments

We thank Bastyr University Research Institute for resources and for housing the MVP study. This team was brought together by the RAND REACH Center, which is supported by the National Center for Complementary & Integrative Health of the National Institutes of Health under Award Number U24AT012549. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Contributions

James F. Morley - Study design, data analysis, first draft of manuscript. Indu Subramanian – Study design, data interpretation, manuscript edits. Joshua Farahnik – Data management, manuscript edits. Leah Grout - Data interpretation, manuscript edits. Cristal Salcido - Data interpretation, manuscript edits. Josi Kurtzer – Data interpretation, manuscript edits. Laurie K. Mischley – study concept, data collection, manuscript edits.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Potential conflict: author LKM owns the copyright of the PRO-PD scale, which was used as an outcome measure in this study; however, LKM was not directly involved in the data management or analysis. Furthermore, LKM has made the PRO-PD scale freely available.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received no financial support for authorship and/or publication of this article. The MVP Study providing these data was initiated with the support of the NIH K01-ATT004404, and has been funded by community donations made by Bill and Sondra Fondren, Mark Claude, Sondra Wolfe Elias, Debbie Krasnow, Mike S., and other anonymous donors.

ORCID iDs

James F. Morley

Leah Grout

References

Leite

SABR

Gonçalves de Oliveira

Diógenes

, et al. Premotor, nonmotor and motor symptoms of Parkinson’s disease: a new clinical state of the art. Ageing Res Rev. 2023;84:101834. doi:10.1016/j.arr.2022.101834

Bloem

Okun

Klein

. Parkinson’s disease. Lancet. 2021;397(10291):2284-2303. doi:10.1016/s0140-6736(21)00218-x

Luo

Qiao

Wen

Zhang

. Global, regional, national epidemiology and trends of Parkinson’s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 2024;16:1498756. doi:10.3389/fnagi.2024.1498756

World Health Organization . Parkinson disease. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease. Updated 9 August 2023. Accessed 27 March, 2024.

National Institute on Aging . Parkinson’s disease: causes, symptoms, and treatments. National Institutes of Health (NIH). https://www.nia.nih.gov/health/parkinsons-disease/parkinsons-disease-causes-symptoms-and-treatments. Updated 14 April 2022. Accessed 27 March, 2024.

de Bie

RMA

Clarke

Espay

Fox

Lang

. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol. 2020;19(5):452-461. doi:10.1016/s1474-4422(20)30036-3

Subramanian

. Complementary and alternative medicine and exercise in nonmotor symptoms of Parkinson’s disease. Int Rev Neurobiol. 2017;134:1163-1188. doi:10.1016/bs.irn.2017.05.037

Caspersen

Powell

Christenson

. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep. 1985;100(2):126-131.

Ernst

Folkerts

Gollan

, et al. Physical exercise for people with Parkinson’s disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;1(1):Cd013856. doi:10.1002/14651858.CD013856.pub2

10.

Brauer

Lamont

O’Sullivan

. A physiotherapy group exercise and self-management approach to improve physical activity in people with mild-moderate Parkinson’s disease: a randomized controlled trial. Trials. 2024;25(1):76. doi:10.1186/s13063-023-07870-4

11.

Crotty

Schwarzschild

. Chasing protection in Parkinson’s disease: does exercise reduce risk and progression? Front Aging Neurosci. 2020;12:186. doi:10.3389/fnagi.2020.00186

12.

Bonde-Jensen

Dalgas

Langeskov-Christensen

. Are physical activity levels, cardiorespiratory fitness and peak power associated with Parkinson's disease severity? J Neurol Sci. 2024;460:122996. doi:10.1016/j.jns.2024.122996

13.

Schenkman

Moore

Kohrt

, et al. Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2018;75(2):219-226. doi:10.1001/jamaneurol.2017.3517

14.

van der Kolk

de Vries

Kessels

RPC

, et al. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial. Lancet Neurol. 2019;18(11):998-1008. doi:10.1016/S1474-4422(19)30285-6

15.

Mak

MKY

Wong-Yu

ISK

. Six-Month community-based brisk walking and balance exercise alleviates motor symptoms and promotes functions in people with Parkinson’s disease: a randomized controlled trial. J Parkinsons Dis. 2021;11(3):1431-1441. doi:10.3233/jpd-202503

16.

de Laat

Hoye

Stanley

, et al. Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia Nigra in Parkinson’s disease. NPJ Parkinson’s Dis. 2024;10(1):34. doi:10.1038/s41531-024-00641-1

17.

Costa

Prati

de Oliveira Barreto Suassuna

Souza Silva Brito

Frigo da Rocha

Gianlorenço

. Physical exercise for treating the anxiety and depression symptoms of Parkinson’s disease: systematic review and meta-analysis. J Geriatr Psychiatry Neurol. 2024;37:415-435. doi:10.1177/08919887241237223

18.

Costa

Aob

Brito

da Rocha

Gianlorenco

. Physical exercise for treating non-motor symptoms assessed by general Parkinson’s disease scales: systematic review and meta-analysis of clinical trials. BMJ Neurol Open. 2023;5(2):e000469. doi:10.1136/bmjno-2023-000469

19.

Ellis

Colón-Semenza

DeAngelis

, et al. Evidence for early and regular physical therapy and exercise in Parkinson’s disease. Semin Neurol. 2021;41(2):189-205. doi:10.1055/s-0041-1725133

20.

Andrejack

Mathur

. What people with Parkinson’s disease want. J Parkinsons Dis. 2020;10(s1):S5-S10. doi:10.3233/jpd-202107

21.

Rafferty

Hoffman

. Parkinson’s foundation exercise convening summary report: the road to creating exercise guidelines and competencies for exercise professionals working with people with Parkinson’s disease. 2021. https://www.parkinson.org/sites/default/files/documents/FINAL_Exercise-ConveningReport5.5.21.pdf. Accessed 27 March 2024.

22.

Patterson

Joslin

Gil

, et al. Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022;23(1):855. doi:10.1186/s13063-022-06703-0

23.

Schootemeijer

de Vries

Macklin

, et al. The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson’s disease (randomized controlled trial). BMC Neurol. 2023;23(1):323. doi:10.1186/s12883-023-03355-8

24.

van Nimwegen

Speelman

Smulders

, et al. Design and baseline characteristics of the ParkFit study, a randomized controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase physical activity in Parkinson patients. BMC Neurol. 2010;10(1):70. doi:10.1186/1471-2377-10-70

25.

Lane

McCrabb

Nathan

, et al. How effective are physical activity interventions when they are scaled-up: a systematic review. Int J Behav Nutr Phys Act. 2021;18(1):16. doi:10.1186/s12966-021-01080-4

26.

Harris

Taylor

Thielke

Payne

Gonzalez

Conde

. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010

27.

Harris

Taylor

Minor

, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208

28.

Hoehn

Yahr

. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442. doi:10.1212/wnl.17.5.427

29.

von Below

Wallerstedt

Bergquist

. Validation of the Swedish patient-reported outcomes in Parkinson’s disease scale in outpatients. Mov Disord. 2023;38(9):1668-1678. doi:10.1002/mds.29517

30.

Nisenzon

Robinson

Bowers

Banou

Malaty

Okun

. Measurement of patient-centered outcomes in Parkinson’s disease: what do patients really want from their treatment? Parkinsonism Relat Disord. 2011;17(2):89-94. doi:10.1016/j.parkreldis.2010.09.005

31.

van der Eijk

Faber

Ummels

Aarts

Munneke

Bloem

. Patient-centeredness in PD care: development and validation of a patient experience questionnaire. Parkinsonism Relat Disord. 2012;18(9):1011-1016. doi:10.1016/j.parkreldis.2012.05.017

32.

Mischley

Lau

Weiss

. Use of a self-rating scale of the nature and severity of symptoms in Parkinson’s Disease (PRO-PD): correlation with quality of life and existing scales of disease severity. NPJ Parkinson’s Dis. 2017;3:20. doi:10.1038/s41531-017-0021-5

33.

Shulman

Armstrong

Ellis

, et al. Disability rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2016;31(10):1455-1465. doi:10.1002/mds.26649

34.

LaHue

Comella

Tanner

. The best medicine? The influence of physical activity and inactivity on Parkinson’s disease. Mov Disord. 2016;31(10):1444-1454. doi:10.1002/mds.26728

35.

Fox

Katzenschlager

Lim

, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248-1266. doi:10.1002/mds.27372

36.

Subramanian

Pushparatnam

McDaniels

Mathur

Post

Schrag

. Delivering the diagnosis of Parkinson’s disease- setting the stage with hope and compassion. Parkinsonism Relat Disord. 2024;118:105926. doi:10.1016/j.parkreldis.2023.105926

37.

Mantri

Fullard

Duda

Morley

. Physical activity in early Parkinson disease. J Parkinsons Dis. 2018;8(1):107-111. doi:10.3233/jpd-171218

38.

Mantri

Wood

Duda

Morley

. Comparing self-reported and objective monitoring of physical activity in Parkinson disease. Parkinsonism Relat Disord. 2019;67:56-59. doi:10.1016/j.parkreldis.2019.09.004

39.

Mantri

Wood

Duda

Morley

. Understanding physical activity in Veterans with Parkinson disease: a mixed-methods approach. Parkinsonism Relat Disord. 2019;61:156-160. doi:10.1016/j.parkreldis.2018.10.023

40.

van Nimwegen

Speelman

Hofman-van Rossum

, et al. Physical inactivity in Parkinson’s disease. J Neurol. 2011;258(12):2214-2221. doi:10.1007/s00415-011-6097-7

41.

Rahimi

Malhotra

Banning

Jenkinson

. Outcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review. BMJ. 2010;341:c5707. doi:10.1136/bmj.c5707

42.

Calvert

Kyte

Duffy

, et al. Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS One. 2014;9(10):e110216. doi:10.1371/journal.pone.0110216

43.

Kyte

Retzer

Ahmed

, et al. Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials. J Natl Cancer Inst. 2019;111(11):1170-1178. doi:10.1093/jnci/djz038

44.

Shu

Yang

, et al. Aerobic exercise for Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9(7):e100503. doi:10.1371/journal.pone.0100503

45.

Chung

Thilarajah

Tan

. Effectiveness of resistance training on muscle strength and physical function in people with Parkinson’s disease: a systematic review and meta-analysis. Clin Rehabil. 2016;30(1):11-23. doi:10.1177/0269215515570381

46.

Yang

Gong

Zhu

Hao

. Tai Chi for improvement of motor function, balance and gait in Parkinson’s disease: a systematic review and meta-analysis. PLoS One. 2014;9(7):e102942. doi:10.1371/journal.pone.0102942

47.

Canning

Sherrington

Lord

, et al. Exercise for falls prevention in Parkinson disease: a randomized controlled trial. Neurology. 2015;84(3):304-312. doi:10.1212/wnl.0000000000001155

48.

Amara

Wood

Joop

, et al. Randomized, controlled trial of exercise on objective and subjective sleep in Parkinson’s disease. Mov Disord. 2020;35(6):947-958. doi:10.1002/mds.28009

49.

David

Robichaud

Leurgans

, et al. Exercise improves cognition in Parkinson's disease: the PRET-PD randomized, clinical trial. Mov Disord. 2015;30(12):1657-1663. doi:10.1002/mds.26291

50.

da Silva

Iop

RDR

de Oliveira

, et al. Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: a systematic review of randomized controlled trials of the last 10 years. PLoS One. 2018;13(2):e0193113. doi:10.1371/journal.pone.0193113

51.

Canning

Allen

Dean

Goh

Fung

. Home-based treadmill training for individuals with Parkinson’s disease: a randomized controlled pilot trial. Clin Rehabil. 2012;26(9):817-826. doi:10.1177/0269215511432652

52.

Schenkman

Hall

Barón

Schwartz

Mettler

Kohrt

. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther. 2012;92(11):1395-1410. doi:10.2522/ptj.20110472

53.

Chen

Tan

Liu

Zhao

. Effect of exercise on quality of life in Parkinson’s disease: a systematic review and meta-analysis. Parkinsons Dis. 2020;2020:3257623. doi:10.1155/2020/3257623

54.

Hallal

Andersen

Bull

Guthold

Haskell

Ekelund

Lancet Physical Activity Series Working Group . Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380(9838):247-257. doi:10.1016/s0140-6736(12)60646-1

55.

Sattelmair

Pertman

Ding

Kohl

3rd Haskell

Lee

. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation (New York, NY). 2011;124(7):789-795. doi:10.1161/circulationaha.110.010710

56.

Hands

Parker

Rose

Larkin

. Gender and motor competence affects perceived likelihood and importance of physical activity outcomes among 14 year olds. Child Care Health Dev. 2016;42(2):246-252. doi:10.1111/cch.12298

57.

Subramanian

Mathur

Oosterbaan

Flanagan

Keener

Moro

. Unmet needs of women living with Parkinson’s disease: gaps and controversies. Mov Disord. 2022;37(3):444-455. doi:10.1002/mds.28921

58.

Korczyn

. Rethinking Parkinson’s disease: a syndromic perspective. Mov Disord. 2024;39(6):1079-1080. doi:10.1002/mds.29833

59.

Ridgel

Phillips

Walter

Discenzo

Loparo

. Dynamic high-cadence cycling improves motor symptoms in Parkinson’s disease. Front Neurol. 2015;6:194. doi:10.3389/fneur.2015.00194

60.

Tsukita

Sakamaki-Tsukita

Takahashi

. Long-term effect of regular physical activity and exercise habits in patients with early Parkinson disease. Neurology. 2022;98(8):e859-e871. doi:10.1212/wnl.0000000000013218

Physical Activity,Patient-Reported Outcomes,and Quality of Life in Parkinson’s Disease

Abstract

Keywords

Introduction

Methods

Data Collection

Outcome Measures

Statistical Analyses

Results

More Frequent PA is Associated with Improved PRO and QoL in PD

Association of Individual Motor and Non-motor PD Symptoms with PA Frequency

Sex-specific Association Between PA, PRO, and QoL in PD

Discussion

Conclusion

Footnotes

Acknowledgments

Author Contributions

Declaration of Conflicting Interests

Funding

ORCID iDs

References